U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C47H74O19
Molecular Weight 943.0791
Optical Activity UNSPECIFIED
Defined Stereocenters 26 / 26
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DESLANOSIDE

SMILES

[H][C@@]1(C[C@H](O)[C@H](O[C@@]2([H])C[C@H](O)[C@H](O[C@@]3([H])C[C@H](O)[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1)O[C@H]5CC[C@@]6(C)[C@]([H])(CC[C@]7([H])[C@]6([H])C[C@@H](O)[C@]8(C)[C@H](CC[C@]78O)C9=CC(=O)OC9)C5

InChI

InChIKey=OBATZBGFDSVCJD-LALPQLPRSA-N
InChI=1S/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68003892

Deslanoside is a cardiotonic glycoside from the leaves of Digitalis lanata. It is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). It also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.

Originator

Stoll, A.|Kreis, W.
1
Sources: Stoll A., Kreis W. Helv. Chim. Acta, 16, 1049, 1390 (1933).
Curator's Comment: Stoll A., Kreis W. Helv. Chim. Acta, 16, 1049, 1390 (1933).

Approval Year

1956
94
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 41.3 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
CEDILANID-D

Approved Use

For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
Primary
Approved
8429
CEDILANID-D

Approved Use

For the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
36 h
REVIEW
https://pubmed.ncbi.nlm.nih.gov/356122
1.6 mg unknown, intravenous
dose: 1.6 mg
route of administration: Intravenous
experiment type: UNKNOWN
co-administered:
DESLANOSIDE serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:31468
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31468
ChemicalBook
CB6683081
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6683081
MolPort
MolPort-006-122-280
https://www.molport.com/shop/molecule-link/MolPort-006-122-280
ZINC
ZINC000253668332
http://zinc15.docking.org/substances/ZINC000253668332
PubMed

PubMed

TitleDatePubMed
Cortical control of neurally mediated arrhythmogenic properties of desacetyllanatoside C.
1981 Mar
Study on cardioactive effects of brazilein.
2006
Characteristics of deslanoside-induced modulation on jejunal contractility.
2012 Nov 7
Patents

Patents

04767720
1

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Intravenous
In Vitro Use Guide
Deslanoside produced significant stimulatory effects (45.3% ± 4.0% vs 87.0% ± 7.8%, P < 0.01) on the contractility of rat jejunal smooth muscle fragment (JSMF) in the low contractile states, and produced significant inhibitory effects (180.6% ± 17.8% vs 109.9% ± 10.8%, P < 0.01) on the contractility of rat JSMF in the high contractile states.
Name Type Language
DESLANOSIDE
EP   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
CEDILANID-D
Brand Name English
DESLANOSIDE [EP MONOGRAPH]
Common Name English
DEACETYLANATOSIDE C
Common Name English
DESLANOSIDE [VANDF]
Common Name English
DESLANOSIDE [MI]
Common Name English
CARD-20(22)-ENOLIDE, 3-((O-.BETA.-D-GLUCOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-12,14-DIHYDROXY-, (3.BETA.,5.BETA.,12.BETA.)-
Common Name English
DESLANOSIDE [JAN]
Common Name English
Deslanoside [WHO-DD]
Common Name English
DESLANOSIDE [ORANGE BOOK]
Common Name English
DESLANOSIDE [MART.]
Common Name English
DESLANOSIDE [USP IMPURITY]
Common Name English
deslanoside [INN]
Common Name English
DESLANOSIDE [USP-RS]
Common Name English
Classification Tree Code System Code
WHO-VATC QC01AA07
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
NCI_THESAURUS C66894
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
NCI_THESAURUS C78322
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
WHO-ATC C01AA07
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
Code System Code Type Description
MERCK INDEX
m4192
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID1022897
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
CHEBI
31468
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
PUBCHEM
28620
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
CAS
17598-65-1
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
ChEMBL
CHEMBL1614
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
DRUG CENTRAL
813
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
IUPHAR
6806
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
NCI_THESAURUS
C65368
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
INN
1581
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
RS_ITEM_NUM
1173009
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
MESH
D003892
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
ECHA (EC/EINECS)
241-568-1
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
WIKIPEDIA
DESLANOSIDE
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
EVMPD
SUB06997MIG
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
SMS_ID
100000092664
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
DRUG BANK
DB01078
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
FDA UNII
YGY317RK75
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY
RXCUI
3248
Created by admin on Fri Dec 15 15:06:42 GMT 2023 , Edited by admin on Fri Dec 15 15:06:42 GMT 2023
PRIMARY RxNorm
ACTIVE MOIETY
Structure of DESLANOSIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966